Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2011-02-18
2011-11-22
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S130100
Reexamination Certificate
active
08062636
ABSTRACT:
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
REFERENCES:
patent: 4818709 (1989-04-01), Primus et al.
patent: 4970071 (1990-11-01), McMichael
patent: 5081235 (1992-01-01), Shivery et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5843708 (1998-12-01), Hardman et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 5877293 (1999-03-01), Adair et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 7011812 (2006-03-01), Griffiths et al.
patent: 2004/0001825 (2004-01-01), Govindan et al.
patent: 2004/0043030 (2004-03-01), Griffiths et al.
patent: 2005/0222392 (2005-10-01), Carter et al.
patent: 2006/0160766 (2006-07-01), Cheung
patent: 0239400 (1987-09-01), None
patent: 0323805 (1989-07-01), None
patent: 0323806 (1989-07-01), None
patent: 91/01990 (1991-02-01), None
patent: 92/01059 (1992-01-01), None
patent: 92/11018 (1992-07-01), None
patent: 95/15769 (1995-06-01), None
patent: 96/01126 (1996-01-01), None
patent: 96/08506 (1996-03-01), None
patent: 96/11013 (1996-04-01), None
Dillman, Journal of Clinical Oncology vol. 12 p. 1497 (1994).
Beckman et al., “Antibody Constructs in Cancer Therapy”, Cancer 109:170-179 (2007).
Begent et al., “Clinical Evidence of Efficient Tumor Targeting Based on Single-Chain Fv Antibody Selected from a Combinatorial Library”, Nat. Med. 2:979-984 (1996).
Berenbaum, M., “Synergy, additivism and antagonism in immunosuppresion”, Clin. exp. Immunol. (1997) 28, 1-18.
Berenbaum, M., “What is Synergy?”, Pharmacol. Rev. 41:93-141 (1989).
Blumenthal et al., “Comparison of Equitoxic Radioimmunotherapy and Chemotherapy in the Treatment of Human Colonic Cancer Xenografts”, Cancer Res., 54:142-151 (1994).
Blumenthal et al., “Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies”, Cancer Res. 52(21):6036-44 (1992).
Blumenthal et al., “Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft”, Cancer Immunol. Immunother. 54(4):315-27 (2005).
Casset et al., “A peptide mimetic of an anti-CD74 monoclonal antibody by rational design”, Biochem. Biophys. Research Comm. 307:198-205 (2003).
Dennis, C. “Off by a Whisker”, Nature 442:739-741 (2006).
Dillman, R., “Antibodies as cytotoxic therapy”, J Clin Oncol. Jul. 1994;12(7):1497-515.
Groninger et al., “Vincristine Induced Apoptosis in Acute Lymphoblastic Leukaemia Cells: A Mitochondrial Controlled Pathway Regulated by Reactive Oxygen Species?” Abstract, Int. J. Oncol. 21:1339-45 (2002).
Hansen et al., “Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen”, Cancer 71:3478-3485 (1993).
Juweid et al., “Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies”, J. Nucl. Med. 37(6):905-11 (1996).
Juweid et al., “Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2”, J Nucl Med. 37(9):1504-10 (1996).
Juweid et al., “Phase I/II Trial of 131I-MN-14 F(ab)2 Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma”, Cancer 85(8):1828-1842 (1999).
Losman et al., “Mimicry of a Carcinoembryonic Antigen Epitope by a Rat Monoclonal Anti-Idiotype Antibody”, Int. J. Cancer 56:580-584 (1994).
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, J. Mol. Biol. 262:732-745 (1996).
Mani et al., “Novel Combinations with Oxaliplatin” Abstract, Oncol. 14:52-8 (2000).
Mayer et al., “Radioimmunoguided Surgery in Colorectal Cancer Using a Genetically Engineered Anti-CEA Single-Chain Fv Antibody”, Clin. Can. Res. 6:1711-1719 (2000).
Muyldermans et al., “Sequence and structure of VH Domain from naturally occurring camel heavy chain immunoglobulins lacking light chains”, Protein Eng. 7(9):1129-35 (1994).
Nap et al., “Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen”, Can. Res. 52:2329-2339 (1992).
Neumaier et al., “Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells”, Can. Res. 50:2128-2134 (1990).
Nowak et al., “Induction of Tumor Cell Apoptosis in Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells”, J. Immunol. 170:4905-13 (2003).
Pascalis et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenetic Humanized Monoclonal Antibody”, J. Immunol. 169:3076-3084 (2002).
Paul, W. (ed.), Fundamental Immunology, Raven Press, NY, 1993, p. 242.
Perez et al., “A Multivalent Recombinant Antibody Fragment Specific for Carcinoembryonic Antigen”, Biotechnol. Appl. Biochem. 43:39-48 (2006).
Primus et al., “Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies”, Cancer Res. 43(2):686-692 (1983).
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor”, Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989).
Ray et al., “Apoptosis Induction of Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11”, Can. Res. 63:4713-23 (2003).
Riechmann et al., “Reshaping human antibodies for therapy”, Nature 332(6162):323-7 (1988).
Rigas et al., “Selective Induction of Colon Cancer Cell Apoptosis by 5-Flourouracil in Humans”, Abstract, Cancer Invest. 20:657-65 (2002).
Senba et al., “Tumor Growth Suppression by a Mouse/Human Chimeric Anti-CEA Antibody and Lymphokine-Activated Killer Cells in Vitro and in SCID Mouse Xenograft Model”, Anticancer Research 18:17-24 (1998).
Sharkey et al., “Murine Monoclonal Antibodies against Carcinoembryonic Antigen: Immunological, Pharmacokinetic, and Targeting Properties in Humans”, Cancer Res. 50:2823-2831 (1990).
Sharkey et al., “Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14”, Cancer 71(6):2082-96 (1993).
Sharkey et al., “Comparison of Tumor Targeting in Nude Mice by Murine Monoclonal Antibodies Directed against Different Human Colorectal Cancer Antigens”, Cancer Res. (Suppl.) 50:828-834 (1990).
Sharkey et al., “Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies”, Cancer Res. 55(23 Suppl):5935s-5945s (1995).
Shibuya et al., “Induction of Apoptosis and/or Necrosis Following Exposure to Antitumour Agents in a Melanoma Cell Line, Probably Through Modulation of Bcl-2 Family Proteins”, Abstract, Melanoma Res. 13:457-64 (2003).
Simoes-Wust et al., “Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide”, Abstract, Breast Cancer Res. 76:157-66 (2002).
Stein et al., “Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma”, Cancer 94:51-61 (2002).
Stein et al., “A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, in
Goldenberg David M.
Hansen Hans J.
Huff Sheela J
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Antibody therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275971